Results 301 to 310 of about 12,501,640 (402)

Cell division responsive peptides for optimized plasmid DNA delivery : the mitotic window of opportunity? [PDF]

, 2014
De Smedt, Stefaan, Demeester, Jo, Lucas, Bart, Remaut, Katrien, Symens, Nathalie   +4 more
core   +1 more source

Gene Targeting and in Vivo Gene Transfer

Cell Transplantation, 1994
openaire   +4 more sources

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Application of multiple sgRNAs boosts efficiency of CRISPR/Cas9-mediated gene targeting in Arabidopsis. [PDF]

BMC Biol
Li J, Kong D, Ke Y, Zeng W, Miki D.
europepmc   +1 more source

Epigenome Modifying Tools In Asthma [PDF]

, 2015
Adcock,, Brook, PO, Durham, AL, Perry, M
core   +1 more source

Generation of gene-modified mice via Cas9/RNA-mediated gene targeting

Cell Research, 2013
Bin Shen, Jun Zhang, Hongya Wu, Jianying Wang, Ke Ma, Zheng Li, Xueguang Zhang, Pumin Zhang, Xingxu Huang   +8 more
semanticscholar   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1. [PDF]

Mol Ther
McIvor RS, Eaton EJ, Webber BR, Moriarity BS.   +3 more
europepmc   +1 more source

Nuclear gene targeting in Chlamydomonas using engineered zinc-finger nucleases.

The Plant Journal, 2013
I. Sizova, André Greiner, M. Awasthi, S. Kateriya, P. Hegemann   +4 more
semanticscholar   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source